通过GLP-1介导的肠关节轴向肠道FXR信号的骨关节炎治疗
Yuanheng Yang1,2, Cong Hao1, Tingying Jiao3,4
1Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.
Science (New York, N.Y.)
|April 3, 2025
概括
一个肠关节轴通过微生物胆汁酸代谢调节骨关节炎. 向这种途径的ursodeoxycholic酸 (UDCA) 可能为骨关节炎提供一种新的治疗方法.
科学领域:
- 微生物学
- 胃肠病学
- 整形医学
背景情况:
- 影响骨关节炎 (OA) 的肠关节轴的存在仍未被探索.
- 在OA患者中观察到肠道微生物胆酸代谢的变化,特别是减少的甘氨酸 (GUDCA).
研究的目的:
- 在骨关节炎调节中研究肠关节轴.
- 探索调节肠道微生物群和胆汁酸代谢的治疗潜力.
主要方法:
- 分析两个独立的OA队列,以确定微生物和代谢变化.
- 在小鼠体内研究,包括抑制或激活Farnesoid X受体 (FXR) 和葡萄糖类1 (GLP-1) 途径.
- 研究Clostridium bolteae和ursodeoxycholic acid (UDCA) 在OA病变和治疗中的作用.
- 对使用UDCA和与OA相关的关节置换风险的人类数据的回顾性分析.
主要成果:
- 降低GUDCA水平和改变胆酸代谢与OA有关.
- 在小鼠中通过GLP-1调节的肠道FXR减轻了OA.
- 在OA患者中观察到*Clostridium bolteae*的丰度降低.
- 通过肠道FXR-关节GLP-1轴给小鼠服用*C. bolteae*和UDCA可以改善骨质炎症.
- 人类UDCA使用与OA相关的关节置换风险降低相关.
结论:
- 一个涉及肠道微生物群,胆酸代谢 (GUDCA),肠道FXR和关节GLP-1信号的新型肠关节轴在OA中起作用.
- 例如,通过UDCA治疗调节这种途径,为骨关节炎提供了一个有前途的治疗策略.
相关概念视频
01:20The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
01:24Glucagon-like Receptor Agonists
280
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
280
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
01:29Inflammatory Bowel Disease IV: Pharmacological Management
83
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
83
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
106
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106
01:26Peptic Ulcer Disease IV: Management
56
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
56